mrecist_assessment: Modified Response Evaluation Criteria in Solid Tumors...

In cliot: Clinical Indices and Outcomes Tools

Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC

Description

Evaluates treatment response in Hepatocellular Carcinoma (HCC) using the mRECIST criteria. Unlike standard RECIST, mRECIST focuses on the viable (arterial enhancing) tumor burden rather than total tumor size, providing a better assessment of response to locoregional therapies.

Usage

mrecist_assessment(target_lesions_sum_change, new_lesions_present,
                   nontarget_lesions_progression, arterial_enhancement_present)

Arguments

target_lesions_sum_change	Numeric. Percentage change in the sum of diameters of viable (enhancing) target lesions compared to baseline (or nadir for progression). (e.g., -30 for 30% decrease, +20 for 20% increase).
new_lesions_present	Numeric (0 or 1). Appearance of new lesions? (1 = Yes).
nontarget_lesions_progression	Numeric (0 or 1). Unequivocal progression of non-target lesions? (1 = Yes).
arterial_enhancement_present	Numeric (0 or 1). Presence of intratumoral arterial enhancement in target lesions? (1 = Yes). Required to distinguish Complete Response from Partial Response.

Value

A list containing:

mRECIST_Response	The calculated response category (CR, PR, SD, PD).
Description	Explanation of the criteria met for the classification.

References

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. doi:10.1055/s-0030-1247132

Examples

# Example 1: Partial Response
# -40% change, no new lesions, enhancement still present
mrecist_assessment(-40, 0, 0, 1)

# Example 2: Progressive Disease (New Lesion)
# -10% change (stable target), but new lesion present
mrecist_assessment(-10, 1, 0, 1)

cliot documentation built on Dec. 1, 2025, 1:06 a.m.